Background: Sodium citrate has antibacterial and anticoagulant properties that are confined to the catheter when used as a catheter lock. Studies of its use as a catheter lock have suggested its efficacy in preventing infection and bleeding complications compared with sodium heparin.
C
entral venous catheters (CVCs) provide vascular access for the majority of patients who are incident on hemodialysis therapy in Europe and the United States and form permanent access for a significant proportion of prevalent patients. 1 However, the relative hazard of death is 1.5 for CVCs compared with arteriovenous fistulae (AVFs), 2 and the relative risk of infection was 7.6 for a CVC versus an AVF in 1 study. 3 When an opportunity exists, an AVF should be formed. We have shown that long-term use of a Tesio-Cath (TC; MedComp, Harleysville, PA) was a reasonable substitute providing good dialysis adequacy with low complication rates when an AVF could not be formed. 4 It is accepted practice to lock CVCs with a volume of sodium heparin (heparin) restricted to the lumen of the catheter to prevent thrombosis and maintain catheter patency between dialysis sessions. Sodium citrate locks (citrate) were used initially as an alternative for patients with heparin sensitivity. 5 However, in vitro, citrate has a demonstrated antibacterial effect, whereas heparin has none. 6 Overspill of 15% to 30% of the catheter lock after injection of a volume of solution equal to the dead space of the CVC specified by the manufacturer is recognized from in vitro studies. 7, 8 Inadvertent spillage of catheter lock and systemic anticoagulation is not desirable for hemodialysis patients who are at heightened risk of bleeding from medical interventions and gastrointestinal causes. This bleeding tendency may be compounded by uremic platelet dysfunction and use of antiplatelet agents. Citrate has an anticoagulant action confined to the catheter because its action is overwhelmed by the concentration of ionized calcium in the systemic circulation. 9 In contrast, small amounts of heparin have a systemic anticoagulant effect because of its greater potency. 10 To date, there have been mainly small and short-term studies suggesting the benefits of citrate over heparin catheter locks on these grounds. [11] [12] [13] [14] One randomized controlled trial comparing 30% citrate with 5% heparin showed a significant decrease in infective and bleeding complications, but the trial was in a mixed group of patients with both acute renal failure and end-stage renal failure (ESRF) with use of both uncuffed and cuffed CVCs.
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Our study is the first randomized controlled trial to compare the use of 46.7% citrate and 5% heparin catheter locks exclusively in patients with ESRF and a single type of cuffed twincatheter single-lumen CVC, the TC, intended as long-term vascular access. We compare the effects of these catheter locks on the primary end point of catheter-related infection and the secondary end points of measures of catheter patency, dialysis efficacy, and bleeding.
METHODS
A total of 232 hemodialysis patients with internal jugular venous TCs (Bio-Flex TC) gave consent and were randomly assigned to open-label treatment for 6 months (Fig 1) . All patients who had been on dialysis therapy for longer than 90 days were eligible. Patients with a bleeding diathesis, an intervention, or pathological state within 3 months of entry that would heighten the risk of bleeding and those with hypocalcemia were excluded from the study. Patients were assigned to treatment arms by using single random-number allocation. However, randomization was unintentionally weighted by a systematic error: odd random numbers from 0 to 9, and including 0, were allocated to citrate (ie, 0, 1, 3, 5, 7, and 9), and even random numbers from 0 to 9 excluding 0 were allocated to heparin (ie, 2, 4, 6, and 8). This resulted in increased treatment allocation to citrate: 132 patients were randomly assigned to citrate, and 100, to heparin.
Administration of Catheter Locks and TC Care
TCs were manipulated by using strict aseptic technique, and catheter locks were instilled slowly in a volume equal to the dead space of the TC to minimize overspill at the end of each dialysis session. Each administration was registered.
Catheter locks were evacuated at the beginning of the next dialysis session. An additional 20 mL of blood was evacuated before venesection for blood tests to avoid contaminating test samples. This blood was then instilled back to the patient after tests had been performed to prevent wastage. The exit site was cleaned at each dialysis session with sterile normal saline followed by chlorhexidine solution, 4%, and air dried before application of a bio-occlusive dressing. No antimicrobial ointment was applied to the exit site. Adverse effects were systematically assessed and recorded at each dialysis session. Patients were asked to report any symptom and were not led by questioning to report any symptom in particular during the course of the study. However, as a result of the consent process, patients were aware that citrate might induce digital and facial paresthesia. Digital and facial paresthesias with the use of citrate were considered an indication of overspill, and the catheter lock volume was reduced by 0.1 mL at the next dialysis treatment.
TC Infection
Dialysis patients with pyrexia, defined as a tympanic temperature of 38°C or greater with or without a systemic inflammatory response were investigated for a TC-related source of infection by means of exit-site swabs and multiple blood cultures before starting antibiotic therapy. Antibiotic therapy starts preempted microbiological confirmation of infection and followed an initial protocol of intravenous vancomycin, 500 mg, after dialysis as Gram-positive cover tailored to maintain trough levels greater than 10 mg/L and oral ciprofloxacin, 250 mg, twice daily as gram-negative cover. Antibiotics were continued according to culture results and antibiotic sensitivity for a minimum of 2 weeks.
Exit-site swabs were used if there were exudates or crust, redness, or induration at the exit site. Exit-site infections were treated initially with oral clarithromycin, 250 mg, twice daily and oral ciprofloxacin, 250 mg, twice daily, and adjustment was made according to response and culture results for a minimum of 2 weeks. Tunnel infections were defined as pain, redness, or induration along the subcutaneous course of the catheter with or without exudates at the exit site. Tunnel infections were treated from the outset with vancomycin and ciprofloxacin, and these were adjusted when culture results were available with the addition of a second appropriate oral antibiotic for a minimum of 4 weeks.
Patients with pyrexia showing a systemic inflammatory response, relative hypotension determined from the indi-vidual patient's usual range for blood pressure, or persistent tunnel infection were admitted to the hospital. Bacteremia alone did not qualify the patient for admission. If TC-related infection resulted in hypotension requiring inotrope support, persistent bacteremia despite antibiotics, or a tunnel infection for longer than 3 days, the TC was removed and a new catheter was sited.
TC Dysfunction
Target blood flow for the TC was 350 mL/min or greater. Suboptimal blood flow less than 250 mL/min and/or decreasing dialysis adequacy was used as a marker for TC dysfunction. Single-pool Kt/V (spKt/V) was measured monthly, and 3 sequential monthly decreases in spKt/V, irrespective of magnitude, defined decreasing dialysis adequacy. Catheter displacement or kinking was excluded by means of a chest x-ray. Each affected patient then had 5,000 units of urokinase locked into each catheter of the TC for 2 hours, and dialysis was reattempted on an outpatient basis. If this strategy failed, patients were admitted to the ward for a 12-hour intraluminal infusion of 12,500 units of urokinase into each catheter of the TC, as previously described in the literature. 16 If this final strategy was unsuccessful, the TC was removed and replaced using the over-the-wire technique. Oral antiplatelet or anticoagulant agents were not used with the intent to improve blood flow rate.
Dialysis Adequacy and Hematologic and Biochemical Variables
All patients had thrice-weekly dialysis using low-flux synthetic AM-BIO-1000Wet hemodialyzers (Asahi Kasei Medical Europe GmbH, Frankfurt, Germany). Dialysis adequacy was measured by using spKt/V on a monthly basis by means of the Daugirdas method. 17 Postdialytic urea was sampled after 1 minute by using the slow-flow method. Measurements of spKt/V were subject to monthly consultant audit, and the dialysis prescription was adjusted to achieve a target spKt/V of 1.6 or greater. Routine hematology and biochemistry tests were performed monthly.
Power, Statistics, and Ethical Permission
The bacteremia rate at our center was established to be 0.68 events/1,000 catheter-days through our participation in a Centers for Disease Control and Prevention study. 18 With recruitment of 100 patients to each arm for this 6-month trial, it was 97% powered to show a 75% decrease in catheter-related bacteremia, the primary end point (␣ ϭ 0.05). This was the magnitude of decrease in bacteremia rates seen in the previous randomized controlled trial. 15 The trial adhered to the Declaration of Helsinki principles and was approved by the St Mary's NHS Trust Local Research Ethics Committee, trial number EC03.106R&D 03/FA/ 005E. An abstract of the trial has been published previously. 19 Parametric data were analyzed by using Student t test, and timeline incidence data were analyzed by using a Poisson model. Kaplan-Meier survival analysis was performed on an intention-to-treat basis for patient survival, TC survival, and adverse-event-free survival. Statistical significance was defined as P Ͻ 0.05.
RESULTS
One hundred thirty-two patients were administered 46.7% citrate catheter locks (DuraLock C; MedComp) and 100 patients were administered 5% heparin catheter locks (Monoparin sodium heparin, 5,000 IU/mL; CP Pharmaceuticals, Wrexham, UK). There were no significant differences between treatment groups at the time of randomization (Table 1) .
Cumulative patient survival at 6 months was 95% for both groups (log-rank test, P ϭ 0.9) censored for drop-out defined by change in dialysis modality, transplantation, or use of an AVF. There were 5 deaths in the citrate group (2 from bronchopneumonia, 2 from sudden cardiac death, and 1 from nonhemorrhagic cerebrovascular accident) and 5 deaths in the heparin group (4 from sepsis unrelated to the CVC, and 1 from sudden cardiac death; Table 2 ).
There were no significant differences in the primary end point of CVC-related bacteremia or exit-site infection rates ( Table 2) . Rates of cumulative survival free of CVC-related bacteremia at 6 months were 91% in the citrate group and 89% in the heparin group (log-rank test, P ϭ 0.7; Fig 2) .
In regard to secondary end points, CVCrelated admission rates and new CVC insertion rates were not significantly different ( Table 2) . Rates of cumulative catheter survival at 6 months with optimal flow were 95% in the citrate group and 100% in the heparin group (log-rank test, P ϭ 0.01; Fig 3) . There was significantly greater use of urokinase locks in the citrate group, but not 12-hour urokinase infusions (Table 2) . Dialysis adequacy was equivalent for both groups (Table 2) . No significant clinical bleeding episodes were seen. Mean hemoglobin and ferritin levels were not statistically different. Blood transfusion and erythropoietin requirements were equivalent for the 2 groups (Table 2) .
Adverse Effects
There were no withdrawals from heparin treatment because of adverse effects. Citrate was associated with more reported side effects. Seventy-one of 132 patients who received citrate (3.72 events/1,000 catheter-days) had side effects (P Ͻ 0.001). These resolved in 24 of 132 patients (34%) with dose reduction. Twenty of 132 patients (15%) receiving citrate withdrew early from the study because of adverse effects of metallic taste and facial and/or digital paresthesia. As a result, citrate treatment was curtailed compared with heparin (mean follow-up, 4.8 Ϯ 2.0 versus 5.7 Ϯ 1.2 months, respectively; P Ͻ 0.001). Cumulative study survival rates after withdrawal for adverse effects were 85% for citrate versus 100% for heparin after 6 months (P ϭ 0.02; Fig 4) .
DISCUSSION
Citrate was not associated with a reduction in infection. There was increased use of thrombolytic therapy to restore functional patency in the citrate arm, but no differences in CVC survival, dialysis adequacy, hospital admissions, or consequences of bleeding. This study is the first randomized controlled trial to compare citrate with heparin as catheter locks for a single twincatheter system in a large number of prevalent hemodialysis patients.
The only randomized controlled trial published to date, by Weijmer et al, 15 analyzed a similar number of patients (n ϭ 291), although only 98 had tunneled cuffed catheters (5 were TCs and the remainder were dual-lumen catheters). Patient demographics was considerably different in their study: 30% were on twiceweekly hemodialysis therapy, 25% were on treatment for acute renal failure rather than established on long-term hemodialysis therapy, and 30% were on oral anticoagulation therapy (coumarins). In the study by Weijmer et al, 15 all enrolled patients had a newly inserted catheter versus 2 patients in our study with a newly inserted TC. Mean catheter vintage in our study was 24 months. Patients were of a younger dialysis vintage in the study by Weijmer et al 15 (mean, 1.2 years on dialysis therapy) compared with our study (mean, 3 years on dialysis therapy). Other studies to date are heterogeneous in terms of design: type of study, concentration of locking solutions, and type of catheter studied (Table 3 ).
In vitro studies had shown that citrate has a dose-dependent antibacterial effect that surpasses heparin related to the chelation of calcium ions and not the osmolality of the solution. 6 Ash et al 11 showed that the bactericidal effect of citrate in vitro was manifest only with concentrations greater than 23%. Shanks et al 20 showed that citrate at a concentration of 2% or greater prevented the in vitro formation of bacterial biofilm by staphylococci on a number of synthetic surfaces. This may help explain in part the antimicrobial effect of citrate catheter locks. In vivo, Ash et al 11 noted a significant decrease in the incidence of catheter-related bacteremia with differing concentrations of citrate in a prospective cohort study of patients with ESRF: the incidence of symptomatic bacteremia was 4.13% with heparin, 1.79% with 23% citrate (P Ͻ 0.05), and 0% with 47% citrate (P Ͻ 0.05). Subsequently, the randomized controlled trial by Weijmer et al 15 compared 30% citrate versus 5% heparin and showed a significant decrease in CVC-related bacteremia with citrate (1.1 versus 4.1 events/1,000 catheter-days; P Ͻ 0.001). Analysis of the 98 patients with tunneled cuffed catheters in this study shows a decrease in CVCrelated bacteremia from 4.2 to 0.8 events/1,000 catheter-days with the use of 30% citrate. These results were used to power our study. However, at our center, we had a much lower bacteremia rate in the control group (0.7 events/1,000 catheter-days) than in the study by Weijmer et al. 15 This could be the result of catheter type and our catheter care protocols and is likely to have reduced the impact of citrate in our study compared with others. A recent Canadian prospective cohort study reported less catheter-related bacteremia in the 4% citrate group, but a change in exit-site care may have confounded the data. 21 No beneficial effect of citrate on the incidence of exit-site infections has been shown. 14, 22 Small controlled studies have reported equivalent short-term patency rates with citrate versus heparin. Buturovic et al 12 showed in 30 patients with ESRF that 4% citrate catheter locks in temporary single-lumen CVCs maintained an equivalent duration of access patency as heparin or polygeline. Stas et al 13 compared 30% citrate catheter locks with 5% heparin catheter locks in 11 patients with ESRF and cuffed double-and single-lumen CVCs using a crossover study design. There were no CVC occlusions, no need for thrombolytics, and no significant differences in thrombus formation for either type of lock. Hendrickx et al 14 prospectively evaluated 5% citrate versus 5% heparin in 19 patients with ESRF with cuffed single-lumen CVCs and found a significantly larger number of dialysis sessions with thrombus formation in those treated with citrate, but no differences in dialysis adequacy, blood flow, number of occlusions, or urokinase use. Weijmer et al 15 found no difference in the num- 23 found no difference in the rate of flow-related catheter change, use of thrombolytic therapy (alteplase), and bacteremias between 4% citrate catheter locks versus 10% heparin catheter locks in a retrospective analysis of their Canadian hemodialysis cohort. In an accompanying Canadian prospective longitudinal cohort study comparing 4% citrate versus 5% heparin catheter locks, there were fewer CVC exchanges and a longer time to thrombolytic use and catheter change in the citratetreated group. 21 It is worth noting that although these 2 studies looked at patients on the hemodialysis program, ie, not treated for reversible acute renal failure and with tunneled CVCs, there was heterogeneity in the type of CVC used, and this may have influenced results. More than 50% of patients in the study by Grudzinski et al 23 were on warfarin therapy, with greater than 80% of these to maintain access patency. It is not clear whether patients were on anticoagulant or antiplatelet treatment in the study by Lok et al. 21 There were no changes in markers of bleeding in our study; patient hemoglobin levels, ferritin levels, and blood transfusion and erythropoietin requirements were similar. No bleeding events were recorded in either group. This is in contrast to Weijmer et al, 15 who found less bleeding in the 30% citrate group. Despite evidence of more overspill in our study with greater concentrations of citrate, the anticoagulant effect of citrate would have been overwhelmed in the circulation. The study by Weijmer et 15 included patients with acute renal failure and uncuffed catheters who might have been at greater risk of bleeding, compounded by the combination of oral anticoagulation in 30%. Only 1 patient in our study was concurrently on warfarin therapy (heparintreated group).
Citrate was associated with a significant number of early withdrawals (15%) because of adverse effects, greater than the 10% quoted in a prior study using 47% citrate. 11 Patients in that study received 47% citrate for only 3 months in a unit with a 10% prevalence of TCs. In a study using a dual-lumen cuffed catheter (AshSplit Cath; MedComp, Harleysville, PA), remarkably, only 1 of 207 patients reported side-effects. 24 Studies show systemic leakage of 15% to 30% of the lock solution in a variety of catheters. 7, 11 An in vitro study showed that the majority leaked from side holes on the catheter tip. 8 The number of symptoms associated with citrate in our study suggests a significant degree of systemic leakage from venous catheters. This may relate to the side holes in TCs. Also, this may relate to our use of the highest concentration of citrate clinically available, which is more dense and thereby more prone to overspill. Overspill also may be caused by variable intraluminal volume because TCs can be cut to a desired length after insertion and repair. Fill volumes are clearly marked on the catheter. As in the study by Weijmer et al, 15 patients were asked to report symptoms after catheter locking in a systematic way in our study, although reporting bias may have influenced results as a consequence of the informed consent process for the trial. Concern about 47% citrate had been raised after a report of a hemodialysis patient who received a total of 10 mL of 47% citrate through a CVC and subsequently experienced cardiac arrest. 25 There were no adverse cardiovascular events in the citrate group in our study. High-dose citrate is not approved by the Food and Drug Administration for use as a catheter-locking solution in the United States.
The financial cost of citrate catheter locks at £8.34/lock was 16 times greater than that for heparin, at £0.5/lock, in the course of this trial. Since the conclusion of the trial, the cost of the citrate lock has decreased to £2.65/lock, with no significant change in the cost of heparin.
Based on the lack of a significant effect on catheter-related infection and the greater rate of adverse effects, widespread use of 46.7% citrate is not justified by this study.
